Superficial acral fibromyxoma with CD10 expression: an underrecognized feature.

G Ital Dermatol Venereol

Section of Clinical, Allergological and Venereological Dermatology, Department of Medicine, University of Perugia, Perugia, Italy -

Published: August 2017

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.16.05349-9DOI Listing

Publication Analysis

Top Keywords

superficial acral
4
acral fibromyxoma
4
fibromyxoma cd10
4
cd10 expression
4
expression underrecognized
4
underrecognized feature
4
superficial
1
fibromyxoma
1
cd10
1
expression
1

Similar Publications

Erythromelalgia, a rare cutaneous pain syndrome, is characterized by acral burning pain and flushing, often alleviated by cold and rest. Primary erythromelalgia is caused by gain-of-function mutations of genes encoding for sodium channels, resulting in hyperexcitability of pain signaling neurons. Autoimmunity and hematologic dyscrasias such as thrombocythemia have been implicated in secondary erythromelalgia.

View Article and Find Full Text PDF

Superficial acral fibromyxoma on the palm: a case report.

J Med Case Rep

January 2025

Department of Clinical Medicine, Jining Medical University, Jining, China.

Background: Superficial acral fibromyxoma is a noncancerous, benign tumor of soft tissue with an unidentified origin. Occurrences of abnormalities on the palm are less frequently documented.

Case Report Presentation: A 47-year-old East Asian woman presented with a palm tumor on her left knuckle that had been present for 4 months.

View Article and Find Full Text PDF

Background: Acral lesions may represent the best/only skin lesions to biopsy in patients suspected to have dermatomyositis (DM). However, histopathologic features of acral DM skin lesions are poorly characterized.

Methods: We reviewed 50 acral biopsies from 46 DM patients and assessed numerous histopathologic features.

View Article and Find Full Text PDF

Introduction: The incidence of melanoma has been increasing in recent decades. BRAF mutations appear in 50%-70% of melanomas. The BRAF-targeted therapy increased the disease-free survival of patients with metastatic melanoma, but this response may be short, due to several resistance mechanisms, such as the presence of other subclones with mutations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!